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BAK activation represents a key step during
apoptosis, but how it converts into a mitochondria-
permeabilizing pore remains unclear. By further
delineating the structural rearrangements involved,
we reveal that BAK activation progresses through a
series of independent steps: BH3-domain exposure,
N-terminal change, oligomerization, and membrane
insertion. Employing a ‘‘BCL-XL-addiction’’ model,
we show that neutralization of BCL-XL by the BH3
mimetic ABT-737 resulted in death only when cells
were reconstituted with BCL-XL:BAK, but not
BCL-2/ BCL-XL:BIM complexes. Although this re-
sembles the indirect model, release of BAK from
BCL-XL did not result in spontaneous adoption of
the pore conformation. Commitment to apoptosis
required association of the direct activator BIM with
oligomeric BAK promoting its conversion to a mem-
brane-inserted pore. The sequential nature of this
cascade provides multiple opportunities for other
BCL-2 proteins to interfere with or promote BAK acti-
vation and unites aspects of the indirect and direct
activation models.
INTRODUCTION
The dynamic interplay between pro- and antiapoptotic mem-
bers of the BCL-2 family dictates life and death decisions. Acti-
vation of the proapoptotic BCL-2 proteins, BAK and BAX (the
effectors), represents the pivotal step toward apoptosis by
mediating mitochondrial outer membrane permeabilization
(MOMP) (Chipuk and Green, 2008; Youle and Strasser, 2008).
Despite their essential role in apoptosis, how effectors are acti-
vated by other BCL-2 family members remains controversial
(Leber et al., 2007). According to the indirect model, antiapop-
totic BCL-2 proteins sequester effectors to block their proapo-
ptotic function. BH3-only proteins can displace BAK or BAXCfrom their antiapoptotic counterparts, thereby facilitating their
oligomerization and subsequent MOMP (Willis et al., 2005). A
competing direct activation model proposes that effector func-
tion is triggered by activator BH3-only proteins, such as BIM
and tBID (Kim et al., 2009; Ruffolo and Shore, 2003; Wei et al.,
2000).
Although the underlying mechanism of activation remains un-
clear, effectors undergomajor structural reorganizations in order
to convert themonomeric, globular, closely packed protein into a
highly ordered, multimeric mitochondrial permeabilizing pore.
The association of BAK with antiapoptotic BCL-2 family mem-
bers, as predicted by the indirect model, occurs through the
canonical BH3:groove interface (Sattler et al., 1997; Willis
et al., 2005). Because the BH3 domain is occluded in inactive
BAK, exposure of the BH3 domain, which coincidentally results
in the opening of the hydrophobic binding groove (BH1–BH3
domains), has to precede BCL-XL association (Moldoveanu
et al., 2006). This conformational change may be induced by
direct association with activators either through the canonical
BH3:groove interface or the BH3 trigger site (a hydrophobic cleft
opposite the canonical groove formed by a1 and a6 helices; Cza-
botar et al., 2013; Leshchiner et al., 2013; Moldoveanu et al.,
2013). The resulting conformation can then engage the BH3
domain of a neighboring effector protein to form a reciprocal,
symmetric, BH3:groove dimer (Dewson et al., 2008). The assem-
bly into high-molecular-weight complexes occurs through a sec-
ond a6:a6 interface (Dewson et al., 2009). In addition, based on a
structural similarity to a-pore-forming toxins (a-PFTs), execution
of effector function may require membrane insertion of the cen-
tral a5/a6 hairpin (pore domain) to form the mitochondria-per-
meabilizing pore (Annis et al., 2005; Griffiths et al., 1999; Makin
et al., 2001; Muchmore et al., 1996).
To further delineate and characterize the steps required for the
transition of native BAK into a membrane-permeabilizing pore,
we combined biochemical and structural approaches to reveal
a progressive sequence of (1) exposure of the BH3 domain, (2)
N-terminal change, (3) oligomerization, and (4) insertion of the
pore domain. By establishing a ‘‘BCL-XL addiction’’ model sys-
tem (Certo et al., 2006), we found that BCL-XL sequesters preac-
tive, BH3-domain-exposed BAK. Release of this checkpoint byell Reports 5, 409–420, October 31, 2013 ª2013 The Authors 409
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Figure 1. BAK and BIM Are Displaced from BCL-XL by ABT-737
(A and B) ABT-737 triggers the intrinsic apoptosis pathway. (A) Jurkat cells were treated with ABT-737 (5 mM) and the percentage of apoptotic cells determined at
the indicated times by using tetramethylrhodamine ethyl ester to measure mitochondrial membrane potential (DJm) and Annexin V staining for the externalization
of phosphatidylserine (PS). Data represent the mean ± SEM from eight different experiments. (B) Processing of caspase-3 and cleavage of PARP were analyzed
following ABT-737 treatment. Cytochrome c release was assessed by digitonin fractionation. HM, heavy membrane fraction.
(C) ABT-737-induced cell death is BAK-dependent. Jurkat cells were transiently transfected with a single BAK siRNA (BAK), a pool of BAK siRNAs (pool), a control
siRNA (con), or left untransfected (ut). After 48 hr, cells were treated with ABT-737 (5 mM) and PS externalization assessed at indicated times. *p < 0.05 compared
to untreated cells. Levels of BAK were analyzed by western blotting.
(D) ABT-737 displaces BAK from BCL-XL. Jurkat cells were treated with ABT-737 (5 mM), lysed in 1%CHAPS, and subjected to immunoprecipitation using either
BAK or BCL-XL antibodies. IP, immunoprecipitation. The asterisk denotes a nonspecific band.
(E and F) ABT-737 displaces BIM from BCL-XL and BCL-2. Cells treated with ABT-737 (5 mM) were subjected to immunoprecipitation for either (E) BIM and
BCL-XL or (F) BIM and BCL-2. The asterisk denotes nonspecific bands.
See also Figure S1.ABT-737 facilitates direct association with BIM promoting mem-
brane insertion and subsequent cell death.
RESULTS
BAK Is Sequestered by BCL-XL and Can Be Released by
the BH3 Mimetic ABT-737
Although the activation of BAK may occur either directly or indi-
rectly, a key feature of both models is the neutralization of anti-
apoptotic BCL-2 proteins by BH3-only proteins. To mimic this,
we used ABT-737, which bindswith high affinity to the hydropho-
bic groove of BCL-XL, BCL-2, and BCL-w and induces apoptosis
in a BAK and/or BAX-dependent manner (Oltersdorf et al., 2005;
van Delft et al., 2006; Vogler et al., 2009). Jurkat cells exposed to
ABT-737 exhibited classical apoptotic characteristics, including
reduction in DJm, increased phosphatidylserine (PS) external-410 Cell Reports 5, 409–420, October 31, 2013 ª2013 The Authorsization, cytochrome c release, and processing of caspase-3
and poly (ADP-ribose) polymerase (PARP) (Figures 1A and 1B).
As these cells lack BAX, ABT-737-induced apoptosis would be
predicted to be solely dependent on BAK (Shawgo et al.,
2008). In agreement with this, suppression of BAK expression
resulted in a marked decrease in PS externalization following
ABT-737 treatment (Figure 1C).
According to the indirect activation model, BAK is held in
check by antiapoptotic proteins (Ruffolo and Shore, 2003; Willis
et al., 2005). Immunoprecipitations revealed that BAK was asso-
ciated with BCL-XL, but not BCL-2 or MCL-1 in Jurkat cells
(Figure 1D; data not shown). ABT-737 antagonized BCL-XL and
efficiently displaced BAK compatible with features of the indirect
model. Closer analysis of the supernatant fractions indicated
that, although the target protein was completely depleted, a
reciprocal reduction in its coprecipitated binding partner was
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Figure 2. Reconstitution of BCL-XL:BAK Complexes Sensitizes Cells to ABT-737
(A and B) Schematic representation of the BCL-XL addictionmodel system as illustrated by the example of BCL-XL:BAK. Bax and BakDKOMEFswere transiently
transfected with BCL-XL (constitutive expression), BAK (under the control of tetracycline [TET]-inducible promoter) and a plasmid encoding the TET-repressor
protein (TETR) to reconstitute BCL-XL:BAK complexes (rec) or with empty vector (con). After 24 hr of BCL-XL expression, BAK was induced for 4 hr with
tetracycline and became complexed with by BCL-XL. ABT-737 neutralizes BCL-XL resulting in the displacement of BAK. (B) Reconstitution of BCL-XL:BAK
complexes sensitizes cells to ABT-737. DKO MEFs reconstituted with BCL-XL:BAK complexes or MOCK-transfected (con) were treated with ABT-737 (3 and
30 mM) for 4 hr and cell death assessed by PS externalization (data points represent themean ± SEM from three different experiments) and caspase-9 processing
(asterisks denote nonspecific bands). *p < 0.05 compared to control; #p < 0.001 compared to untreated reconstituted cells.
(C) Induced BAK associates with BCL-XL and is displaced by ABT-737. BCL-XL:BAK-reconstituted or MOCK-transfected (con) DKO MEFs were treated with
ABT-737 (3 mM) for 4 hr, lysed in 1% CHAPS, and subjected to immunoprecipitation using a BCL-XL antibody.
(D and E) ABT-737-released BIM does not induce apoptosis in reconstituted cells. BAK was replaced with BIM, and HEK293T cells were reconstituted with
BCL-XL:BIM, BCL-2:BIM, or as a control BCL-XL:BAK complexes. BIM-reconstituted cells were exposed to ABT-737 (5 or 10 mM) for 3 hr and (D) externalization of
PS was determined (data points represent the mean ± SEM from three different experiments) or (E) BCL-2 or BCL-XL was precipitated from CHAPS lysates using
StrepTactin Sepharose.
(F) The BAK BH3 domain is involved in association with BCL-XL. BAK BH3 mutants L78A and D83A were introduced into the reconstitution system in HEK293T
cells or MOCK-transfected (con). Cells were lysed in 1% CHAPS and lysates subjected to immunoprecipitation using a BCL-XL antibody.
See also Figure S2.not observed (Figure 1D, box). Thus, only a discrete portion of
BAK appeared to be complexed with BCL-XL.
The direct activator BIM was also released from BCL-2 and
BCL-XL by ABT-737, and although its displacement was less effi-
cient compared to BAK, released BIM could potentially act to
‘‘directly’’ activate inactive BAK (Figures 1E, 1F, and S1).
Reconstitution of BCL-XL:BAK Complexes Results in
Sensitivity to ABT-737
If the release of BAK from BCL-XL is functionally important for
ABT-737-induced apoptosis, then introduction of BCL-XL:BAKCcomplexes into resistant cells should sensitize them to ABT-
737. To exclude interference from endogenous Bak or Bax,
BCL-XL:BAK complexes were introduced into Bax and Bak dou-
ble-knockout (DKO) mouse embryonic fibroblasts (MEFs). As
coexpressing BAK with BCL-XL resulted in cell death, we first
expressed BCL-XL followed by tetracycline-induced expression
of BAK (Figure 2A). Upon induction, BAK autoactivates but
is then inhibited by a ‘‘sink’’ of BCL-XL resulting in cells with
BAK precomplexed to BCL-XL exclusively. Reconstitution of
BCL-XL:BAK complexes sensitized DKO MEFs to ABT-737 as
assessed by PS externalization and processing of caspase-9ell Reports 5, 409–420, October 31, 2013 ª2013 The Authors 411
(Figure 2B). As in this model system, all induced BAK was
sequestered, effectively ‘‘addicting’’ the cells to BCL-XL (Fig-
ure 2C, box), and ABT-737-induced cell death was a result of
BAK release from BCL-XL. Reconstitution of cells with MCL-
1:BAK did not confer sensitivity to ABT-737 validating our model
system (Figures S2A and S2B).
Introduction of BCL-XL:BIM or BCL-2:BIM complexes into
human embryonic kidney 293T (HEK293T) cells did not alter
sensitivity to ABT-737 (Figures 2D and 2E). Thus, BIM released
from BCL-2 or BCL-XL did not appear to exert a direct activator
function on endogenous BAK or BAX, further suggesting that the
reconstituted BCL-XL:BAK complexes are the preferential target
of ABT-737. The model was then extended to characterize
BCL-XL:BAK complexes. BAK associates with BCL-XL through
the canonical BH3:groove association (Sattler et al., 1997). In
agreement, introduction of BAK BH3 mutants L78A or D83A
into the reconstitution system revealed that, whereas both coim-
munoprecipitated with BCL-XL, they were, in contrast to wild-
type (WT) BAK, also recovered from the supernatant (Figure 2F).
This implied both mutants displayed a reduced affinity for
BCL-XL and confirmed the requirement of the BH3 domain for
complex formation. As this domain is occluded in inactive
BAK, BCL-XL sequesters a preactivated, BH3-domain-exposed
conformation.
BAK N-Terminal Change Occurs Downstream of and
Independent from BH3 Domain Exposure
In addition to BH3 domain exposure, conformational changes
within the N-terminal region are also characteristic of BAK acti-
vation and are commonly determined by exposure of the Ab-1
epitope and increased trypsin sensitivity (Griffiths et al., 1999;
Wei et al., 2000). Limited trypsin proteolysis onmitochondria iso-
lated from ABT-737-treated Jurkat cells revealed a BAK cleav-
age fragment (p19), which was only detectable with the GLY82
antibody (epitope in the BH3 domain). In contrast, antibodies
directed against the N-terminal region (NT and Ab-1) revealed
a reduction in full-length BAK without detection of the p19 frag-
ment, linking trypsin sensitivity to N-terminal change (Figures 3A,
3B, and S3). Together with formation of the p19 fragment, Ab-1-
associated fluorescence was also detectable and occurred in
the entire cell population, but not when cells were treated with
an inactive enantiomer of ABT-737 (Figure 3C). Thus, N-terminal
change required the neutralization of antiapoptotic proteins by
ABT-737 and, by inference, this must occur downstream of
BAK displacement from BCL-XL.
To further explore the relationship between displacement and
N-terminal change, we established a double immunoprecipita-
tion procedure: the first was directed against Ab-1-exposed
BAK, followed by a second, on the resulting supernatant, against
BCL-XL (Figure 3D). When Jurkat cells were lysed in CHAPS (to
retain BAK in its native conformation), Ab-1 failed to precipitate
BAK and the BCL-XL:BAK complex was recovered from the re-
sulting supernatant (Figure 3E, box). Thus, BAK complexed
with BCL-XL had not yet exposed the Ab-1 epitope. ABT-737
treatment resulted in the recovery of BAK by Ab-1, but BCL-XL
failed to coprecipitate suggesting that BAK exposes this epitope
downstream of its release from BCL-XL (Figure 3E). This was
confirmed by the second immunoprecipitation, which recovered412 Cell Reports 5, 409–420, October 31, 2013 ª2013 The AuthorsBCL-XL without associated BAK. Taken together, these data
demonstrated that the BAK N-terminal change occurred down-
stream of its displacement from BCL-XL.
As the BAK BH3 domain is required for association with
BCL-XL, this further inferred that eversion of the BH3 domain
occurred independent of and upstream of the N-terminal
change. In addition, when the N terminus of BAK was artificially
altered by Triton X-100, the BCL-XL:BAK complex was recov-
ered in both immunoprecipitations (Figure 3E; Dewson et al.,
2008). Thus, under these conditions, BCL-XL-sequestered
BAK existed as a heterogeneous population of BH3-domain-
exposed/Ab-1-exposed as well as BH3-domain-exposed/Ab-
1-occluded conformations. Identical mixed conformations
were also obtained by double immunoprecipitation with recon-
stituted cells solubilized in CHAPS and ABT-737 treatment,
which resulted in conversion to an exclusively N-terminal
changed population (Figure 3F). Thus, the N terminus can be
altered either artificially with detergents or by ‘‘overexpression’’
without affecting the BH3:groove association highlighting the
independence of both events.
BAK Oligomerizes following N-Terminal Change, a
Pivotal, but Not Sufficient, Step toward MOMP
The oligomerization of BAK into dimers and high-molecular-
weight complexes is a prerequisite for MOMP and can be as-
sessed using the redox catalyst copper(II)(1,10-phenanthroline)3
(CuPhe) (Dewson et al., 2008; Falke et al., 1988). In untreated
Jurkat cells, CuPhe induced the formation of an intramolecular
disulfide bond between N-terminal C14 and a6-localized C166
resulting in a fastermigrating bandonSDS-PAGE (Mx) (Figure 4A,
left panel). ABT-737 treatment shifted the MX form into disulfide-
linked dimers (D) and higher molecular weight complexes (DX).
Reduction of disulfide bonds resulted in the detection of solely
monomeric BAK (Figure 4A, right panel).
Oligomerization involves two distinct interfaces, the BH3
domain/groove and the a6 helix (Dewson et al., 2008, 2009).
As the a6 helix is occluded by a1 helix in inactive BAK, the N-ter-
minal change has to precede oligomerization. To analyze the
chronology of the N-terminal change and oligomerization, BAK
was restrained in its MX conformation prior to activation. After in-
cubation at 42C to activate BAK (Pagliari et al., 2005), oligomer
formation as well as cytochrome c release was reduced
compared to ‘‘unrestrained’’ BAK (Figures 4B and 4C). These re-
sults indicated that the N-terminal change must precede oligo-
merization possibly to enable exposure of the oligomerization
interface, the a6 helix, to the protein surface.
Interference with the BH3:groove interface by utilizing a BAK
L78A or an N-terminal-truncated BAKDN83, which lacks amajor
part of the BH3 domain, did not impair oligomer formation (Fig-
ures 4D and S4B). Despite undergoing oligomerization, L78A
BAK failed to induce apoptosis as assessed by PS externaliza-
tion and cytochrome c release (Figures 4E, 4F, and S4A). Oligo-
merization was not an artifact as L78A BAK also under-
went N-terminal change, a prerequisite for oligomerization
(Figure 4F). Therefore, the ability to oligomerize did not appear
to determine the proapoptotic activity of BAK suggesting the
requirement of additional steps to convert BAK into a mem-
brane-permeabilizing pore.
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Figure 3. N-Terminal Change Occurs Downstream of the Release of BAK from BCL-XL
(A) Schematic representation of BAK and location of Ab-1, NT, and GLY82 antibody epitopes are indicated. The trypsin cleavage site is marked by an arrow, and
the resulting p19 fragment is shown.
(B) The BAK N terminus became trypsin-sensitive following ABT-737 treatment. Mitochondria from ABT-737-treated Jurkat cells (5 mM for indicated times) were
isolated by Dounce homogenization and subjected to limited trypsin proteolysis. Cleavage of BAK was analyzed using a panel of BAK antibodies (Gly82, NT, and
Ab-1). PefablocSC (inhibitor) was included as a control.
(C) The Ab-1 epitope is exposed following ABT-737 treatment. Jurkat cells were treated with ABT-737 (5 mM) or its inactive enantiomer (5 mM) for the indicated
times. Cells were then labeled with BAK Ab-1/ALEXA488-labeled antibodies (open histogram) or secondary antibody alone (con, filled histogram) and analyzed
for Ab-1-associated fluorescence by flow cytometry.
(D) Double immunoprecipitation procedure to determine N-terminal conformation of BCL-XL-sequestered BAK. A first immunoprecipitation is directed
against N-terminally changed BAK using the Ab-1 antibody. The resulting supernatant fraction is then subjected to a second immunoprecipitation against
BCL-XL.
(E) Ab-1 exposure occurs downstreamof BAK displacement fromBCL-XL. ABT-737-treated Jurkat cells (5 mM for the indicated times) were lysed in 1%CHAPS or
1% Triton X-100 and lysates subjected to double immunoprecipitation.
(F) Reconstituted BAK is present as mixed population of N-terminal exposed and occluded forms. BCL-XL:BAK-reconstituted or MOCK-transfected (con) DKO
MEFs were treated with ABT-737 (30 mM) for 4 hr and lysed in 1% CHAPS. Lysates were subjected to double immunoprecipitation (as detailed in D).
See also Figure S3.BAK Inserts Its Pore Domain into the Outer
Mitochondrial Membrane
Membrane insertion of the BAX pore domain is associated
with the formation of a MOMP-inducing pore (Annis et al.,
2005; Antonsson et al., 1997; Schlesinger et al., 1997). We hy-
pothesized that, following oligomerization, BAK inserts its pore
domain into themembrane and the L78Amutantmay be blocked
at this stage accounting for its inactivity. The membrane topol-
ogy of the a5/a6 hairpin in WT versus L78A BAK was analyzed
by combining cysteine mutagenesis with 4-acetamido-40-
((iodoacetyl) amino) stilbene-2,20-disulfonic acid (IASD) labelingC(Annis et al., 2005; Krishnasastry et al., 1994). IASD only labels
sulfydryl groups exposed to a hydrophilic environment resulting
in the labeling of cysteine residues in the cytosol, the cyto-
plasmic boundary of a pore, or those facing the lumen of an
aqueous pore. Cysteines embedded within the lipid bilayer or
buried within a protein interface will be protected from IASD
labeling (Figure 5A).
Cysteines were introduced in the pore domain of WT and
L78A BAK using cysteine-deficient BAK (C14A/C166A) as a
template. Insertions did not appreciably affect proapoptotic
activity when overexpressed in DKO MEFs (Figure S5). Asell Reports 5, 409–420, October 31, 2013 ª2013 The Authors 413
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Figure 4. Oligomerization Does Not Represent the Final Step for Commitment to Apoptosis
(A) BAK oligomerizes during apoptosis. Jurkat cells were treatedwith ABT-737 (5 mM) for the indicated times. Mitochondria were then isolated and disulfide bonds
introduced using CuPhe. Formation of BAK dimers and oligomers was analyzed by western blotting under nonreducing conditions (left panel) and specificity of
bands confirmed using reducing conditions (right panel). Mx, intramolecular-disulfide bond, inactive BAK; M, monomeric BAK; D, intermolecular-disulfide bond,
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(B and C) Restraining BAK in the MX conformation impairs its proapoptotic function. Enriched mitochondrial fractions from control Jurkat cells were exposed to
two different concentrations of CuPhe. ‘‘MX-trapped’’ BAK was then heat-activated (42
C for 30 min) followed by analysis of (B) disulfide-linked oligomer for-
mation and (C) cytochrome c release.
(D) BAK L78A still oligomerizes. WT and L78A BAK were transiently transfected into DKO MEFs. Oligomer formation was assessed 24 hr posttransfection using
CuPhe and western blotting under nonreducing conditions.
(E) The BAK BH3 mutant, L78A, fails to induce apoptosis in Bax and Bak DKO MEFs. The asterisk denotes p < 0.05, and L78A was significantly different from
wild-type.
(F) L78A BAK undergoes N-terminal change but fails to release cytochrome c. DKO MEFs were transfected with WT or L78A BAK for 24 hr; fixed, permeabilized,
and stained with Ab-1 (green), Hoechst 33342, and anti-cytochrome c (red); and examined by confocal microscopy. L78A BAK-staining colocalized with
mitochondria but did not release cytochrome c in contrast to WT BAK.
See also Figure S4.BAK is constitutively membrane-anchored, a cysteine insertion
at residue L195 within the transmembrane region (a9 helix)
served as a control. Following overexpression in DKO MEFs,
both WT and L78A L195C exhibited an unaltered mobility on
SDS-PAGE compared to the unlabeled control (Figure 5B).
This protection from IASD labeling represented membrane
insertion, as solubilization in CHAPS resulted in an IASD-medi-
ated increase in molecular weight. In contrast, the N-terminal
endogenous cysteine C14 in both WT and L78A was labeled
by IASD indicating the constitutive cytosolic localization
(Figure 5B).414 Cell Reports 5, 409–420, October 31, 2013 ª2013 The AuthorsIf the killing conformations of BAK and BAX are analogous,
then the a5/a6 hairpin should be embedded in the membrane
and, as a result, cysteines within these helices would be ex-
pected to be protected from IASD labeling (Annis et al.,
2005). Conversely, if membrane insertion of the L78A mutant
is impaired, then the corresponding cysteines would remain
cytosolic and thus modified by IASD. In contrast a cysteine
insertion at N124 (first N-terminal residue of the a5 helix) as
well as the endogenous cysteine C166 (on the C-terminal end
of the a6 helix) were modified by IASD in both WT and L78A
BAK (Figure 5B). However, as both cysteines localize to the
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See also Figure S5.extremities of the a5 and a6 helices in WT BAK, they could
represent the cytoplasmic boundary of a membrane-inserted
pore domain (Figure 5A).
Cysteine residues with a more centralized localization within
the a5/a6 helices should therefore be protected in the ‘‘killing
conformation’’ of WT BAK. Despite this, residues R137C (a5
helix) as well as WT V154C and R156C (both a6 helix) were
also labeled by IASD (Figure 5B). However, the labeling pattern
of the corresponding L78A mutants differed by the presence of
an IASD-protected species. Solubilization with CHAPS resulted
in a complete shift to a labeled band, thus excluding the occlu-
sion of these cysteines in a protein-protein interface and demon-
strating there was sufficient IASD for labeling. These results
indicated that the pore domain of L78A adopts a different mem-
brane topology to WT BAK possibly explaining opposing
apoptotic activities of WT and L78A BAK.
BIM Promotes Insertion of the BAK Pore Domain
The different membrane topologies of WT compared to L78A
BAK imply that adoption of the killing conformation was depen-
dent on the BH3 domain. As the BH3 domain is part of the
groove, the nonkilling, IASD-protected conformation of L78A
could result from impaired engagement of a ‘‘ligand’’ BH3
domain which can be provided by a direct activator. In support
of this hypothesis, we found that coexpression of the directCactivator BIM with WT, but not L78A BAK, promoted cell death
(Figure 6A). This synergism correlated with the coimmunopreci-
pitation of BIM with WT BAK, but not with the L78A mutant
(Figure 6B). In this coexpression approach, WT BAK is already
oligomerized when transfected alone indicating a role of BIM
downstream of oligomerization possibly by promoting mem-
brane insertion (Figure 6C).
In agreement, BIM altered the membrane topology of WT
R137C or V154C by inducing a shift from the unlabeled to the
IASD-labeled species (Figure 6D, box). Importantly, BIM did
not alter the labeling pattern of the corresponding L78Amutants.
However, both L78A andWTBAKgave a double bandwhichwas
associated with cell death only with WT, but not L78A BAK. A
similar pattern was also observed when WT BAK was overex-
pressed at an intermediate killing concentration (Figure S6A).
Thus, the double band obtained with WT and L78A BAK may
represent different membrane topologies.
To further investigate the effects of BIM on BAK, BIM expres-
sion was knocked down in the reconstitution system. Reduction
of BIM expression resulted in a decrease of ABT-737-induced
cell death (Figure 6E). We hypothesized that this effect should
correlate with retention of WT R137C and V154C BAK in an
IASD-protected nonkilling conformation (Figures 6D and S6A).
Agreeing with this, WT R137C was predominantly IASD-
labeled and suppression of BIM resulted in reversion ofell Reports 5, 409–420, October 31, 2013 ª2013 The Authors 415
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Figure 6. BIM Alters Membrane Topology of the a5/a6 Hairpin of WT but Not L78A BAK
(A) Coexpression of WT, but not L78A BAK, with BIM promotes proapoptotic activity. WT or L78A BAK was coexpressed with BIM in Bax and Bak DKO MEFs,
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complexes were reconstituted and treated with ABT-737 (5 mM for 3 hr). HM fractions were generated and subjected to IASD labeling.
See also Figure S6.the labeled to an unlabeled species which was independent of
release from BCL-XL by ABT-737 (Figure 6F). When
reconstituted, BCL-XL sequestered oligomeric BAK and
thus this does not contradict the proposed order of oligo-
merization followed by membrane insertion (Figures S1, 4A,
and S6B). WT V154C gave a mixture of labeled and unlabeled
species, and suppression of BIM reduced the IASD-labeled
species, although this effect was only evident following
ABT-737 treatment (Figure 6F, box). Taken together,
these data revealed that the proapoptotic activity of WT
BAK correlated with the conversion of an IASD-protected to
a labeled conformation, which was promoted by interaction
with BIM.416 Cell Reports 5, 409–420, October 31, 2013 ª2013 The AuthorsDISCUSSION
BAK and BAX are essential effectors of MOMP, the point of
no return in apoptotic cell death, and as a consequence, their
activation must be highly regulated. In this study, we demon-
strate that activation of BAK involves several sequential but inde-
pendent conformational changes, which provide different regu-
latory checkpoints mediated by members of the BCL-2 family.
The antiapoptotic arm of this family functions to sequester a
BH3-domain-exposed conformation of BAK preventing its
further activation. BH3 mimetics, such as ABT-737, can release
this checkpoint facilitating N-terminal change and oligomeriza-
tion. The ability to oligomerize, however, did not correlate with
cell death, and formation of a MOMP-inducing pore required as-
sociation with the direct activator BIM.
The Initial Steps: BH3 Domain Exposure, N-Terminal
Change, and Oligomerization
In agreement with the indirect activation model, we validated a
role for BCL-XL andMCL-1, but not BCL-2, in inhibiting BAK acti-
vation (Ruffolo and Shore, 2003; Wei et al., 2000; Willis et al.,
2005; Figures 1, 2, and S2). BAK associates with BCL-XL through
the canonical BH3:groove interface, which is stabilized by hydro-
phobic and electrostatic interactions. Interference with either
(L78A or D83A BAK BH3 mutants) reduced binding to BCL-XL
(Figures 1D, 2C, and 2F; Sattler et al., 1997). By competing for
the groove of BCL-XL, ABT-737 displaced BAK from BCL-XL
further establishing the importance of the BH3:groove associa-
tion (Figures 1D and 2C; Oltersdorf et al., 2005). In inactive
BAK, key stabilizing hydrophobic residues within the BH3
domain face the protein core and association with BCL-XL
requires rotation of the BH3 domain-containing a3 helix to
evert these residues to the protein surface. This change involves
the opening of the otherwise occluded hydrophobic groove
(BH1–BH3 domains). Thus, BCL-XL does not sequester inactive
BAK but a preactivated, BH3-domain-exposed/open-groove
conformation.
In contrast to BAK, in BAX the a9 helix (transmembrane
anchor) occludes the groove/BH3 domain. Its disengagement
is required to expose the BH3 domain/groove, which may be
allosterically induced by association of activators with the BH3
trigger side to induce an N-terminal change (Cartron et al.,
2004; Gavathiotis et al., 2008). Thus, for BAX, N-terminal change
precedes exposure of the BH3 domain/groove which is accom-
panied by translocation to the mitochondria. As BAK constitu-
tively localizes to the mitochondria and the a1/a6 binding site
is not as pronounced, it has been proposed that BAK can bypass
this activation step resulting in constitutive exposure of the N ter-
minus (Kim et al., 2009). However, several lines of evidence sug-
gest that the N terminus is initially occluded. Exposure of a
cryptic antibody epitope (Ab-1), increased trypsin sensitivity,
as well as the loss of the Mx form are associated with the N-ter-
minal change and exclusively occurred following ABT-737 treat-
ment (Griffiths et al., 1999; Wei et al., 2000; Figures 3B, 3C, and
4D). By mapping the Ab-1 epitope to Y38 to the middle of the a1
helix, we attribute the increased accessibility to this epitope to a
major reorganization of the N-terminal region (a1 and a2 helices)
rather than the simple exposure (Figure S3). However, despite
the close proximity of the N-terminal region with the BH3
domain, the N-terminal change occurred independent and
downstream of BH3 domain exposure as BCL-XL-sequestered
BAK existed exclusively in an N-terminal-occluded conformation
(Figures 3E and 3F). Furthermore, the N-terminal change is a pre-
requisite for oligomerization, as the formation of oligomers could
be blocked by inhibiting the N-terminal change (Figures 3C, 4A,
and 4B). This supports the proposed model for oligomerization
as the N terminus occludes the a6 helix which represents the
interface for BH3:groove-linked dimers to associate into oligo-
mers (Dewson et al., 2008, 2009). However, the apparent, indis-
pensable role of the BH3 domain in oligomer formation is unclear
as both BAKDN83 as well as BAK L78A both form oligomersC(Figures 4D and S4B). Although BAK is oligomeric in the recon-
stitution system, BH3 domains appear to be available both to
facilitate a BH3:groove association with BCL-XL and to allow
interaction with BIM (Figures 6B and S6B). Despite this, the
BH3 domain clearly contributes to BAK proapoptotic function,
as both BAKDN83 as well as L78A lost their killing ability (Figures
4E and S4A). Thus, in analogy to BAX, a BH3-domain-dependent
step must occur downstream of oligomerization (Kushnareva
et al., 2012).
The BAK BH3 Mutant, L78A, Is Blocked at a Prepore
Conformation
Structural similarities between a-PFTs prompted the hypothesis
that BAK and BAX insert into the membrane to mediate MOMP
(Muchmore et al., 1996). The membrane-inserting domains of
a-PFTs are composed of a hydrophobic, central, helical hairpin
which, in the native conformation, is surrounded by amphipathic
helices. During activation, a series of conformational changes
opens up these outer layers to expose the central hairpin, which
then spontaneously penetrates the membrane (Parker et al.,
1990). By analogy, during BAK activation, the outer a1 helix re-
positions away from the protein core exposing the a6 helix,
which together with the a5 helix resembles the central hairpin
of the PFTs. However, the pore domain of BAK is comprised of
largely amphipathic helices, which are not expected to sponta-
neously membrane insert. The occlusion of polar surfaces within
tertiary contact sides may energetically favor membrane inser-
tion (Walker et al., 1992, 1995). By analogy, BAK assembled
into high-molecular-weight complexes prior to membrane inser-
tion (membrane anchored conformation; Figure S7i) and conse-
quently could be labeled by IASD (Figures 5B and 6D; labeled
band with L78A R137C and V154C). This effectively concen-
trated these subunits on the membrane surface potentially
facilitating the coordinated membrane insertion (Figure S7ii).
Evidence for a membrane-inserted conformation was suggested
by the protection of R137C and V154C from IASD when using
sublethal concentrations of WT BAK (Figure 6D) or in L78A
BAK (Figures 5B and 6D). However, this labeling pattern was
not associated with killing and consequently could not represent
the final pore but rather a prepore conformation (Figures S6 and
S7ii). In contrast, when WT BAK R137C and V154C were
expressed at killing concentrations, they were accessible to
IASD (Figure 5B). Considering that in active BAK the a5 and a6
helices have to adopt a transmembrane/membrane-inserted
conformation (Oh et al., 2010), accessibility to IASD could be
explained by the localization of these residues to the lumen of
an aqueous pore. In support of this, amphipathic helices, like
the pore domain of BAK, were shown to orientate their polar
patches toward the lumen of the pore to expose nonpolar sur-
face to the hydrophobic core of the bilayer (Gonza´lez-Man˜as
et al., 1993; Lakey et al., 1992). BAX is also described to form
an ion-conductive, aqueous pore implying that polar residues
within the pore domain must orientate to the lumen of the
pore (Antonsson et al., 1997; Schlesinger et al., 1997). Thus,
several lines of evidence point toward a membrane-inserted
pore domain lining the lumen of an aqueous MOMP pore. This
provides a possible explanation for the observed shift from unla-
beled to labeled conformations which correlated with cell death.ell Reports 5, 409–420, October 31, 2013 ª2013 The Authors 417
The pore domain seemed to reorientate within the membrane
from a state where the pore domain was ‘‘partially’’ inserted
into the membrane (IASD-protected) to the mature MOMP-
inducing pore (IASD-labeled). As pore formation appeared to
be a highly dynamic process (Figure S6A), a continuous flux
from membrane-anchored to pore conformation could occur,
possibly explaining the detection of double bands under certain
conditions.
BIM Promotes the Conversion of Prepore BAK to the
Pore Conformation
Multidomain BCL-2 family members, such as BAK, are capable
of acting both as ligand or receptor. Inserting its BH3 domain
into the hydrophobic binding groove of antiapoptotic BCL-2 pro-
teins affords BAK ligand characteristics, whereas the structurally
juxtaposed BH1–BH3 domains form a hydrophobic groove,
which can act as a receptor for the BH3 domain of direct acti-
vator proteins (Czabotar et al., 2013; Kim et al., 2009; Leshchiner
et al., 2013). Activator engagement promotes the exposure of the
effector BH3 domain and opening of the groove, thereby
creating the interfaces required for oligomerization.
In our model, we could not find any direct activator role of BIM
on endogenous BAK or BAX following its release from BCL-XL
(Figure 2D). However, the importance of direct activators in the
initial activation of both BAK and BAX has been demonstrated
recently using ‘‘BH3-stabilized a helices of BCL-2 proteins’’ or
BH3 peptides on recombinant full-length or truncated effectors
(Czabotar et al., 2013; Leshchiner et al., 2013; Moldoveanu
et al., 2013).
In agreement, BIM synergized with BAK proapoptotic function
as coexpression of both proteins enhanced and vice versa and
decrease of BIM levels reduced cell death (Figures 6A and 6E).
This effect was only evident withWT, but not L78A BAK, implying
the requirement of an intact receptor surface to accommodate
the BH3 domain of the activators. The direct activator role of
BIM is attributed to the induction of BAK oligomerization (Cheng
et al., 2001; Kim et al., 2009). However, in both model systems
used, coexpression or reconstitution, BAK was oligomerized
prior to BIM association (Figures 6C and S6B). Although we
cannot exclude a possible involvement of BIM in the initial acti-
vation of BAK, our results suggest BIM can also act downstream
of oligomerization in an unappreciated role to convert the mem-
brane topology of oligomerized, partially membrane-inserted
prepore BAK to the killing pore conformation. This hypothesis
is supported by our finding that coexpression of BIM shifted
WT R137C and V154C from an IASD-protected to a labeled spe-
cies, whereas knockdown of BIM reversed this (Figures 6D and
6F). The N-terminal part of the a5 helix (amino acids 124–136)
comprises the BH1 domain and thus participates in groove for-
mation. Complete membrane insertion of this helix would effec-
tively destroy the hydrophobic groove causing a loss of receptor
characteristic. This would suggest that in prepore BAK, protec-
tion from IASD-labeling may represent the partial insertion of
the a5 helix to maintain the structure and function of the groove
and thus facilitate engagement with the BIM BH3 domain (Fig-
ures 6D and 6F). BIM could then promote conformational
changes within the groove leading to complete insertion of the
pore domain.418 Cell Reports 5, 409–420, October 31, 2013 ª2013 The AuthorsIn summary, our results reveal that BAK activation is a com-
plex process that includes a series of independent steps (Fig-
ure 7). Although BAK adopts an oligomeric conformation after
its release from BCL-XL, this conformation does not induce
MOMP. We have identified a requirement for the direct activator
BIM to convert oligomerized prepore BAK into a membrane-per-
meabilizing pore. Therefore, BAK activation does not exclusively
occur through the direct or indirect activation models but rather
combines aspects of both. These additional steps provide
further unappreciated checkpoints to control activation and pre-
vent unwanted/accidental cell death and also open up possible
opportunities for tumors to deregulate apoptosis.
EXPERIMENTAL PROCEDURES
Detailed description of cell culture, immunoprecipitation, limited proteolysis,
Ab-1 staining, transfection methods, and cell death analysis are provided in
the Extended Experimental Procedures.
Constructs
pcDNA3.1, pcDNA4TO, pcDNA6, and pcDNA6-TetR were obtained from
Invitrogen. Human BAK was cloned into pcDNA4TO with an N-terminal
Strep-Tag II. Strep-Flag double-tagged BCL-XL and BIMEL were cloned into
pcDNA6. Constructs were transiently transfected into Bax and Bak DKO
MEFs (obtained from Drs. A. Strasser and D. Huang, The Walter and Eliza
Hall Institute of Medical Research) using JetPrime (Polyplus) or HEK293T cells
using Jet PEI (Polyplus) according to manufacturer’s protocol. Where indi-
cated, site-directed mutagenesis was performed using QuikchangeMulti (Agi-
lent Technologies), and all constructs were sequence-verified prior to use.
Reconstitution of BCL-XL:BAK Complexes
Cells were transiently transfected with BAK, TetR, and BCL-XL constructs at
ratios 1:10 (BAK:TetR) and 1:1 (BAK:BCL-XL). BAK was induced with tetracy-
cline (4 mg/ml; Calbiochem) at 24 hr posttransfection for 4 hr prior to treatment
with ABT-737.
Analysis of BAK Oligomers Using CuPhe
Formation of BAK high-molecular-weight complexes was analyzed using the
redox catalyst CuPhe. Mitochondria-enriched fractions from Jurkat cells or
digitonin-generated heavy membrane fractions from MEFs were solubilized
in X-link Buffer (100 mM sucrose, 20 mM HEPES-KOH [pH 7.4], 2.5 mM
MgCl2, and 50 mM KCl) and incubated with CuPhe (20 mM 1,10 phenanthro-
line with 300mMCuSO4) for 30min on ice. The reaction was then quenched by
incubation with 100 mM EDTA for 15 min and mitochondria-enriched fractions
recovered. Oligomerization of BAK was analyzed by SDS-PAGE under nonre-
ducing conditions.
Assessment of BAK Membrane Topology Using IASD Labeling
BAK cysteine insertion mutants were transiently transfected into DKO MEFs
or HEK293T cells. Heavy membrane fractions were obtained by mild digitonin
lysis and washed with 10 mM dithiothreitol (DTT) to ensure reduction of
sulfydryl groups. Pellets were resuspended in X-link buffer and incubated
with 10 mM IASD for 30 min at room temperature. Reactions were quenched
by addition of 100 mM DTT and mitochondria-containing fractions recovered.
Resulting pellets were solubilized in 2% CHAPS and IASD modification
analyzed by SDS-PAGE followed by western blotting on large-format
SDS-PAGE gels. As controls, samples were left unlabeled or lysed in 2%
CHAPS prior to IASD labeling.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.09.010.
Figure 7. Schematic Model of BAK Activation
Inactive BAK is monomeric and adopts a closely packed, globular conformation with both the BH3 domain and groove occluded. Eversion of key hydrophobic
residues within the BH3 domain to the protein surface results in groove opening and facilitates association with BCL-XL through a BH3:groove interface. This
interaction with BCL-XL serves as a checkpoint to block further activation of BAK, therebymaintaining cell survival. Neutralization of BCL-XL by ABT-737 results in
the release of BAK, which then undergoes anN-terminal change followed by oligomerization. Activation of BAK up to this point is compatible with activation by the
indirect model. Oligomerized BAK assumes a prepore conformationwith the a5/a6 helices partially inserted in themitochondrial membrane. Association with BIM
results in the conversion of preporeWTBAK into a fully membrane-inserted, membrane-permeabilizing porewith the subsequent release of cytochrome c and the
induction of apoptosis. BIM fails to interact with oligomerized and partially membrane-inserted BAK L78A, which remains in its inactive ‘‘prepore’’ conformation.
Thus, the activation of BAK reflects an interplay between direct and indirect activation models.
See also Figure S7.ACKNOWLEDGMENTS
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